Mendus AB (publ) (IMMU) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you. First of all, everybody, thanks for joining on what is a sunny day here in Stockholm for the Mendes Q1 financial report and business update. In Q1, we reported the feedback we got from the regulatory agencies on our preparations for a registration trial with our lead product, Vida Densel and AML, and that feedback was supportive of our efforts, both in terms of the trial design and other trial-related preparations, but also with respect to our next steps that will move the production of the product towards large-scale GMP production. It's important we stay close to the regulators and ask them for feedback regularly to make sure that we are moving in the right direction. And that was something we confirmed in a press release earlier this year. We also are preparing a deeper pipeline of earlier stage trials to address broader patient populations in acute myeloid leukemia but also related diseases like chronic myeloid leukemia and we presented supportive data end of last year at ASH in that direction and we have ongoing research programs to support those efforts but also we are actually starting to prepare for those trials as part of our deeper trial pipeline. As an important part of the overall late-stage development strategy, we are setting up large-scale GMP manufacturing, so manufacturing of video-dense cell products for clinical use. It's a very important step not only to support the late-stage clinical development, but also in the end to make sure we have a commercially attractive product that is ready to be launched in the market. We started the expansion of the clinical development of ididenza with a trial called AMLM22 cadence. It's a trial that is managed by the Oscillation Leukemia and Lymphoma Group. And we were happy to report that the first pati...